Abzena vs Lonza: CDMO Comparison
Side-by-side comparison of Abzena and Lonza on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Lonza has FDA inspections on record (2); Abzena does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Lonza holds 3 active EMA GMP certificates; Abzena does not appear in EudraGMDP.
- Lonza maintains 5 MHRA / UK GMP certificates; Abzena does not.
- Composite Signal Score: Lonza 78/100 vs Abzena 64/100 — a 14-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both Abzena and Lonza qualify as ADC manufacturers; Lonza carries the higher composite Signal Score for ADC programs in this comparison.
What to evaluate for ADC programs
Both Abzena and Lonza qualify as ADC CDMOs. When choosing between them for ADC programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
HPAPI containment
Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.
Linker-payload chemistry on file
Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.
Commercial bioconjugation track record
Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.
Integrated DS + DP
Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.
Frequently asked: Abzena vs Lonza
Which has the stronger FDA inspection record, Abzena or Lonza?
Both Abzena and Lonza maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Abzena has 0 FDA inspections on record; Lonza has 2.
How do Abzena and Lonza compare on European GMP coverage?
Abzena holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Lonza holds 3 active EMA GMP certificates and 5 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Abzena or Lonza?
Abzena is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Lonza is matched to 1. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for ADC manufacturing — Abzena or Lonza?
Both Abzena and Lonza are tagged as ADC CDMOs in our directory, so both are credible options for ADC programs. The most important differentiator for ADC selection is typically hpapi containment: Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Abzena carries a Signal Score of 64/100 and Lonza carries 78/100 — a meaningful lead for Lonza. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →